Return on Equity (ROE)
since 2005
Calculation
Regeneron Pharmaceuticals Inc., ROE, long-term trends, calculation
| ROE | = | 100 | × | Net income (loss)1 | ÷ | Stockholders’ equity1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 15.03% | = | 100 | × | 4,412,600) | ÷ | 29,353,600) |
| Dec 31, 2023 | 15.22% | = | 100 | × | 3,953,600) | ÷ | 25,973,100) |
| Dec 31, 2022 | 19.14% | = | 100 | × | 4,338,400) | ÷ | 22,664,000) |
| Dec 31, 2021 | 43.03% | = | 100 | × | 8,075,300) | ÷ | 18,768,800) |
| Dec 31, 2020 | 31.86% | = | 100 | × | 3,513,200) | ÷ | 11,025,300) |
| Dec 31, 2019 | 19.08% | = | 100 | × | 2,115,800) | ÷ | 11,089,700) |
| Dec 31, 2018 | 27.91% | = | 100 | × | 2,444,400) | ÷ | 8,757,300) |
| Dec 31, 2017 | 19.51% | = | 100 | × | 1,198,511) | ÷ | 6,144,078) |
| Dec 31, 2016 | 20.13% | = | 100 | × | 895,522) | ÷ | 4,449,245) |
| Dec 31, 2015 | 17.40% | = | 100 | × | 636,056) | ÷ | 3,654,837) |
| Dec 31, 2014 | 13.69% | = | 100 | × | 348,074) | ÷ | 2,542,325) |
| Dec 31, 2013 | 21.74% | = | 100 | × | 424,362) | ÷ | 1,952,076) |
| Dec 31, 2012 | 60.24% | = | 100 | × | 750,269) | ÷ | 1,245,385) |
| Dec 31, 2011 | -45.65% | = | 100 | × | (221,760) | ÷ | 485,732) |
| Dec 31, 2010 | -19.79% | = | 100 | × | (104,468) | ÷ | 527,815) |
| Dec 31, 2009 | -17.10% | = | 100 | × | (67,830) | ÷ | 396,762) |
| Dec 31, 2008 | -19.75% | = | 100 | × | (82,710) | ÷ | 418,852) |
| Dec 31, 2007 | -22.94% | = | 100 | × | (105,600) | ÷ | 460,267) |
| Dec 31, 2006 | -47.24% | = | 100 | × | (102,337) | ÷ | 216,624) |
| Dec 31, 2005 | -83.72% | = | 100 | × | (95,446) | ÷ | 114,002) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in thousands
The financial data reveals significant fluctuations in net income over the observed periods. Initially, the company experienced consistent losses from 2005 through 2011, with the net income (loss) figures deepening from approximately -95 million USD in 2005 to over -220 million USD by 2011. A notable turnaround occurs in 2012, where net income shifts dramatically to a positive 750 million USD, marking the beginning of a sustained period of profitability. Subsequently, net income demonstrates a generally upward trend, peaking around 8.1 billion USD in 2021, before declining somewhat in the last two recorded years to approximately 4.4 billion USD in 2024.
Stockholders’ equity exhibits a steady and robust growth over the entire timeframe. Starting from roughly 114 million USD in 2005, equity increases with some acceleration after 2010. By 2012, the equity exceeds 1.2 billion USD and continues to expand rapidly thereafter, reaching nearly 29.4 billion USD by 2024. This growth suggests ongoing capital accumulation and retention of earnings, reflective of the company’s improving profitability and possibly capital injections or other equity-enhancing activities.
The Return on Equity (ROE) metric corroborates the trends observed in net income and equity. Negative ROE values prevail until 2011, signifying unprofitable operations relative to shareholder investments, with the most extreme negative value around -83.72% in 2005. The year 2012 marks a significant recovery, with a positive ROE of 60.24%, indicating highly efficient use of equity capital during that year. While the ROE peaks early in the profitable phase, it stabilizes mostly in the range of approximately 15% to 43% in subsequent years. This stabilization points to consistent profitability and effective equity utilization, albeit at lower margins compared to the initial rebound.
In summary, the company transitioned from a prolonged period of losses to sustained profitability beginning in 2012. This transition is supported by substantial growth in stockholders’ equity and improved efficiency as evidenced by ROE metrics. Despite fluctuations in the net income figures post-peak, the overall financial trajectory indicates strong operational performance and growing equity base in recent years.
- Net Income
- Losses through 2011 with a turning point in 2012, followed by growth to a peak in 2021 and a moderate decline thereafter.
- Stockholders’ Equity
- Consistent growth over the entire period, accelerating post-2010 and reaching nearly 29.4 billion USD by 2024.
- Return on Equity (ROE)
- Negative until 2011, sharp positive rebound in 2012, then stabilization in the range of 15% to 43%, reflecting improved profitability and equity utilization.
Comparison to Competitors
Regeneron Pharmaceuticals Inc., ROE, long-term trends, comparison to competitors
| Regeneron Pharmaceuticals Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 15.03% | 128.66% | 69.59% | -54.78% | 7.87% | 74.62% | 2.48% | 19.68% | 36.96% | 9.11% | 12.78% | -3.26% |
| Dec 31, 2023 | 15.22% | 46.94% | 107.78% | 27.27% | 8.91% | 48.65% | 24.81% | 51.11% | 0.97% | 2.38% | 12.83% | 20.59% |
| Dec 31, 2022 | 19.14% | 68.60% | 178.97% | 20.37% | 14.39% | 58.64% | 21.62% | 23.36% | 31.57% | 32.79% | 15.80% | 23.88% |
| Dec 31, 2021 | 43.03% | 74.91% | 87.96% | 19.46% | 14.24% | 62.16% | 29.55% | 28.20% | 34.17% | 28.47% | 18.94% | 23.19% |
| Dec 31, 2020 | 31.86% | 35.30% | 77.20% | -23.84% | 9.17% | 109.79% | 0.68% | 23.25% | 27.91% | 15.21% | 18.47% | 31.22% |
| Dec 31, 2019 | 19.08% | — | 81.07% | 6.66% | 9.94% | 319.09% | 23.91% | 25.42% | 37.99% | 25.77% | 12.45% | 19.34% |
| Dec 31, 2018 | 27.91% | — | 67.15% | 35.07% | 9.40% | 32.88% | 25.51% | 25.60% | 23.30% | 17.59% | 10.65% | 47.28% |
| Dec 31, 2017 | 19.51% | 104.16% | 7.84% | 8.58% | 9.45% | -1.76% | 22.64% | 2.16% | 6.97% | 29.47% | 8.76% | 12.99% |
| Dec 31, 2016 | 20.13% | 128.41% | 25.85% | 27.55% | 11.10% | 19.54% | 71.48% | 23.49% | 9.78% | 12.12% | 9.39% | -9.69% |
| Dec 31, 2015 | 17.40% | 130.39% | 24.71% | 10.97% | 14.17% | 16.53% | 97.70% | 21.66% | 9.94% | 10.75% | 9.25% | -59.19% |
| Dec 31, 2014 | 13.69% | 101.84% | 20.01% | 13.49% | 11.11% | 15.55% | 78.45% | 23.40% | 24.50% | 12.81% | 9.22% | -68.70% |
| Dec 31, 2013 | 21.74% | 91.90% | 23.00% | 16.91% | 12.04% | 26.57% | 27.05% | 18.68% | 8.85% | 28.83% | 7.55% | -32.81% |
| Dec 31, 2012 | 60.24% | 156.85% | 22.80% | 14.39% | 12.58% | 27.69% | 27.84% | 16.74% | 11.63% | 17.93% | 7.62% | -10.71% |
| Dec 31, 2011 | -45.65% | — | 19.35% | 23.25% | 12.85% | 32.11% | 41.60% | 16.94% | 11.50% | 12.18% | 8.84% | 3.76% |
| Dec 31, 2010 | -19.79% | — | 19.32% | 19.74% | 13.08% | 40.82% | 49.48% | 23.57% | 1.58% | 9.40% | 6.74% | -149.74% |
| Dec 31, 2009 | -17.10% | — | 20.32% | 71.49% | 9.90% | 45.45% | 41.40% | 24.25% | 21.85% | 9.59% | 5.51% | -58.57% |
| Dec 31, 2008 | -19.75% | — | 20.58% | 42.86% | 13.43% | -30.76% | 48.43% | 30.46% | 41.63% | 14.08% | 6.66% | -192.51% |
| Dec 31, 2007 | -22.94% | — | 17.72% | 20.50% | 15.08% | 21.61% | 46.69% | 24.41% | 18.01% | 12.53% | 5.25% | -144.23% |
| Dec 31, 2006 | -47.24% | — | 15.56% | 15.86% | 16.89% | 24.25% | -65.54% | 28.11% | 25.25% | 27.10% | 1.21% | -40.89% |
| Dec 31, 2005 | -83.72% | — | 17.96% | 26.77% | 17.67% | 18.34% | 26.88% | 27.49% | 25.85% | 12.32% | 7.99% | -85.05% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Regeneron Pharmaceuticals Inc., ROE, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Regeneron Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2024 | 15.03% | 15.57% |
| Dec 31, 2023 | 15.22% | 20.65% |
| Dec 31, 2022 | 19.14% | 27.99% |
| Dec 31, 2021 | 43.03% | 29.75% |
| Dec 31, 2020 | 31.86% | 17.22% |
| Dec 31, 2019 | 19.08% | 27.68% |
| Dec 31, 2018 | 27.91% | 26.29% |
| Dec 31, 2017 | 19.51% | 14.59% |
| Dec 31, 2016 | 20.13% | 22.19% |
| Dec 31, 2015 | 17.40% | 21.44% |
| Dec 31, 2014 | 13.69% | 20.91% |
| Dec 31, 2013 | 21.74% | 20.33% |
| Dec 31, 2012 | 60.24% | 18.27% |
| Dec 31, 2011 | -45.65% | 15.52% |
| Dec 31, 2010 | -19.79% | 13.99% |
| Dec 31, 2009 | -17.10% | 20.34% |
| Dec 31, 2008 | -19.75% | 21.31% |
| Dec 31, 2007 | -22.94% | 17.07% |
| Dec 31, 2006 | -47.24% | 21.86% |
| Dec 31, 2005 | -83.72% | 19.08% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Regeneron Pharmaceuticals Inc., ROE, long-term trends, comparison to industry (health care)
| Regeneron Pharmaceuticals Inc. | Health Care | |
|---|---|---|
| Dec 31, 2024 | 15.03% | 14.75% |
| Dec 31, 2023 | 15.22% | 18.50% |
| Dec 31, 2022 | 19.14% | 22.94% |
| Dec 31, 2021 | 43.03% | 23.78% |
| Dec 31, 2020 | 31.86% | 15.95% |
| Dec 31, 2019 | 19.08% | 21.79% |
| Dec 31, 2018 | 27.91% | 18.65% |
| Dec 31, 2017 | 19.51% | 14.05% |
| Dec 31, 2016 | 20.13% | 18.22% |
| Dec 31, 2015 | 17.40% | 18.18% |
| Dec 31, 2014 | 13.69% | 18.58% |
| Dec 31, 2013 | 21.74% | 18.25% |
| Dec 31, 2012 | 60.24% | 17.51% |
| Dec 31, 2011 | -45.65% | 15.27% |
| Dec 31, 2010 | -19.79% | 14.32% |
| Dec 31, 2009 | -17.10% | 19.27% |
| Dec 31, 2008 | -19.75% | 19.00% |
| Dec 31, 2007 | -22.94% | 16.88% |
| Dec 31, 2006 | -47.24% | 20.24% |
| Dec 31, 2005 | -83.72% | 18.16% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).